Entheses and bones in spondyloarthritis: 2008 Annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)

Journal of Rheumatology

Volumn 36, Issue 7, 2009, Pages 1527-1531

  Colbert, Robert A ^a,k   Deodhar, Atul A ^b   Fox, David ^c   Gravallese, Ellen M ^d   Khan, Muhammad Asim ^e   McGonagle, Dennis ^f   Reveille, John D ^g   Schett, Georg ^h   Weisman, Michael ⁱ   Clegg, Daniel O ^j  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

Ankylosing spondylitis; Epidemiology; Spondyloarthritis; Spondyloarthropathies

Indexed keywords

AMINOPEPTIDASE; HLA B27 ANTIGEN; INTERLEUKIN 23 RECEPTOR; PROTEIN ARTS1; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BONE DESTRUCTION; CONFERENCE PAPER; CONTINUING EDUCATION; HUMAN; INFLAMMATION; OSSIFICATION; PRIORITY JOURNAL; REGISTER; SPONDYLOARTHROPATHY; SYNOVIUM; TH17 CELL; UNITED STATES;

BONE AND BONES; HUMANS; OSTEITIS; OSTEOGENESIS; RHEUMATIC DISEASES; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 67650487201     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090122     Document Type: Conference Paper

References (46)

1. Ward MM, Bruckel J, Colbert R, et al. Summary of the 2005 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 2005;33:978-82.
2. Khan MA, Clegg DO, Deodhar AA, et al. 2006 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 2007;34:1118-24.
3. Colbert RA, Deodhar AA, Khan MA, et al. 2007 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 2008;35:1398-402.
4. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998;352:1137-40.
5. Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat 2001;199:503-26.
6. Puhakka KB, Jurik AG, Schiottz-Christensen B, et al. MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study. Scand J Rheumatol 2004;33:332-8.
7. Benjamin M, Toumi H, Suzuki D, Redman S, Emery P, McGonagle D. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007;56:224-33.
8. McGonagle D, Wakefield RJ, Tan AL, et al. Distinct topography of erosion and new bone formation in achilles tendon enthesitis: Implications for understanding the link between inflammation and bone formation in spondylarthritis. Arthritis Rheum 2008;58:2694-9.
9. McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007;56:2482-91.
10. Benjamin M, McGonagle D. Histopathologic changes at "synovio- entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum 2007;56:3601-9.
11. Grainger AJ, Farrant JM, O'Connor PJ, et al. MR imaging of erosions in interphalangeal joint osteoarthritis: is all osteoarthritis erosive? Skeletal Radiol 2007;36:737-45.
12. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
13. Lubberts E, Oppers-Walgreen B, Pettit AR, et al. Increase in expression of receptor activator of nuclear factor kappa B at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002;46:3055-64.
14. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
15. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
16. Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002;196:77-85.
17. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-33.
18. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
19. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2845-51.
20. Jimenez-Boj E, Redlich K, Turk B, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005;175:2579-88.
21. Hayer S, Polzer K, Brandl A, et al. B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res 2008;23:1650-60.
22. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008;58:649-56.
23. Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52.
24. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-7.
25. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
26. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.
27. Maksymowych WP, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-53.
28. Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204:2803-12.
29. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008;180:214-21.
30. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
31. Colbert RA. HLA-B27 misfolding activates the IL-23/IL-17 axis via the unfolded protein response in transgenic rats: evidence for a novel mechanism of inflammation [abstract]. Arthritis Rheum 2007;56 Suppl:S515.
32. Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: Implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum 2007;56:215-23.
33. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
34. Tremelling M, Cummings F, Fisher SA, et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007;132:1657-64.
35. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.
36. Werman A, Werman-Venkert R, White R, et al. The precursor form of IL-1 alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 2004;101:2434-9.
37. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006;83:447S-55S.
38. Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002;110:515-26.
39. Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003;171:6814-9.
40. Layh-Schmitt G, Colbert RA. The interleukin-23 / interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol 2008;20:392-7.
41. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74:304-5.
42. Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007;34:2285-90.
43. Akkoc N, Khan MA. Epidemiology of ankylosing spondylitis and related spondyloarthropathies. In: Weisman MH, Reveille JD, van der Heijde DM, editors. Ankylosing spondylitis and the spondyloarthropathies: A companion to Rheumatology. London: Mosby-Elsevier; 2006:117-31.
44. Onen F, Akar S, Birlik M, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008;35:305-9.
45. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
46. Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995;34:1074-7.